South Carolina’s largest sterile CDMO recognized for visionary leadership, innovation, and community impact at SCbio’s annual Life + Science Conference.
COLUMBIA, S.C. – February 20, 2026 – The Ritedose Corporation is honored to have received the 2026 S.C. Life Sciences Pinnacle Award for Organizational Contribution, presented by SCbio during its annual Life + Science Conference in Charleston. The recognition was among the highlights of the largest one-day life sciences industry event in the Palmetto State, which drew more than 400 life science leaders from across South Carolina and the United States.
The S.C. Life Sciences Pinnacle Award for Organizational Contribution recognizes an entity whose performance over time has exemplified visionary leadership, unwavering commitment to innovation, and a deep dedication to advancing the life sciences sector. Ritedose was selected for delivering superior outcomes, elevating its workforce, and enriching communities across South Carolina and beyond.
“We are honored to receive the S.C. Life Sciences Pinnacle Award for Organizational Contribution,” said Jody Chastain, President and Chief Executive Officer, The Ritedose Corporation. “This recognition reflects our team’s collective commitment to uncompromising quality, because patients depend on the drugs we produce. We continue to invest in our capabilities and our community, from expanding our facilities to pledging one million doses of essential respiratory medicines through our partnership with Dispensary of Hope. We are grateful for this honor and excited to continue making a positive impact in South Carolina’s life sciences community.”
For Ritedose, the award represents more than recognition. It reflects the company’s deep pride in being part of the life sciences community. As a member-driven economic development organization, SCbio unifies academia, startups, government, and established enterprises around a shared mission to positively impact humanity through science. The life sciences industry in South Carolina generates $20.1 billion in annual economic impact and supports 63,000 jobs across the state, and Ritedose is proud to contribute to that legacy.
As the largest sterile contract development manufacturing organization (CDMO) in the United States specializing in Blow-Fill-Seal (BFS) technology, Ritedose guides the development of molecules from clinical trials through commercialization of branded and generic inhalation and ophthalmic medications. The company’s focus on quality, innovation, and patient outcomes continues to drive meaningful investment in both its people and its infrastructure.
About The Ritedose Corporation
Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow-Fill-Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company’s process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information, visit ritedose.com.
